Bristol-Myers Squibb Company (BMY)
|Net Income (ttm)||-5.08B|
|Ex-Dividend Date||Sep 30, 2021|
|Day's Range||60.17 - 61.10|
|52-Week Range||55.46 - 69.75|
|Price Target||80.06 (+32.9%)|
|Est. Earnings Date||Oct 27, 2021|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and ps... [Read more...]
Financial PerformanceFinancial Statements
According to 19 analysts, the average rating for BMY stock is "Buy." The 12-month stock price forecast is 80.06, which is an increase of 32.92% from the latest price.
Maybe, but not if you're looking for major growth over the short term.
Market sell-offs are perfectly normal and an opportune time to invest in great companies at a discount.
Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.
Bristol Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.32% move from the prior day.
Drug stocks are in a tailspin, and you need to look no farther than Washington for the primary reason. A White House plan to cut the price of medications has led to a more than 10% drop in the Dow Jones...
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking A...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BLA--U.S. FDA Accepts for Priority Review Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination...
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Nega...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Opdivo + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal....
In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.23, marking a -1.24% move from the previous day.
Bristol Myers Squibb Co (NYSE: BMY) announced Opdivo (nivolumab) plus Yervoy (ipilimumab) long-term survival data in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC)....
Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overa...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO21--Five-Year Data from CheckMate -214 Show Opdivo Plus Yervoy Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial.....
Don't miss out on these two thriving businesses.
Bristol Myers Squibb & Co (NYSE: BMY) announced three-year data from the CheckMate -743 trial demonstrating a durable survival benefit with first-line treatment with Opdivo (nivolumab) plus Yervoy (ipil...
According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact ...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #cancer--According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment...
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three Years Compared to Chemothe...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO21--Opdivo + Yervoy Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural....
In the latest trading session, Bristol Myers Squibb (BMY) closed at $63.13, marking a -0.71% move from the previous day.
Bristol Myers Squibb Shares Research Supporting Correlation Between New York Heart Association Functional Class (NYHA...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Cardio--BMS Shares Research Supporting Correlation between NYHA class and Mortality in Obstructive Hypertrophic Cardiomyopathy
NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Dividend
BOLT collaborates with Bristol Myers to investigate its pipeline candidate BDC-1001 in combination with the latter???s Opdivo.
Final Trades: Bristol Myers, Marathon Petroleum, Zoetis & more
The "Halftime Report" traders give their top picks to watch for the second half.
NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021